Christine R. Klaus

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

Sarah K. Knutson, Natalie M. Warholic, Tim J. Wigle et al. · Proceedings of the National Academy of Sciences · 2013 · 757 citations · Full text

Engineering, Chemoprevention Strategy, Smarcb1-deleted Mrt Cells +24

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Sarah K. Knutson, Tim J. Wigle, Natalie M. Warholic et al. · Nature Chemical Biology · 2012 · 753 citations

Lymphoid Neoplasia, Medicine, Selective Inhibitor +8

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen et al. · Blood · 2013 · 718 citations · Full text

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i> -Mutant Non-Hodgkin Lymphoma

Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima et al. · Molecular Cancer Therapeutics · 2014 · 517 citations

EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity

John E. Campbell, Kevin W. Kuntz, Sarah K. Knutson et al. · ACS Medicinal Chemistry Letters · 2015 · 127 citations · Full text

Pharmacotherapy, A Potent, Ezh2 Activity +17